Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical Setting

Publication date

2019-08-29

Authors

Economopoulou, Panagiota
de Bree, RemcoORCID 0000-0001-7128-5814ISNI 0000000387040744
Kotsantis, Ioannis
Psyrri, Amanda

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

Abstract

Head and neck squamous cell carcinoma (HNSCC) represents a group of tumors arising in the oral cavity, oropharynx, and larynx. Although HNSCC is traditionally associated with tobacco and alcohol consumption, a growing proportion of head and neck tumors, mainly of the oropharynx, are associated with Human Papilloma Virus (HPV). Recurrent/metastatic disease is characterized by dismal prognosis and there is an unmet need for the development of biomarkers for detection of early disease, accurate prediction of prognosis, and appropriate selection of therapy. Based on the REMARK guidelines, a variety of diagnostic and prognostic biomarkers are being evaluated in clinical trials but their clinical significance is doubtful. Herein, we will focus on biomarkers in HNSCC used in the clinical setting and we will illustrate their clinical relevance.

Keywords

Biomarkers, HPV, Head and neck cancer, Immunoscore, PD-L1, PET/CT scan, Tobacco, Oncology, Cancer Research

Citation

Economopoulou, P, de Bree, R, Kotsantis, I & Psyrri, A 2019, 'Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical Setting', Frontiers in oncology, vol. 9, no. AUG, 827. https://doi.org/10.3389/fonc.2019.00827